AN2 Therapeutics, a biopharma company focused on small molecules, plans to lay off approximately half of its 41 employees across research, manufacturing, clinical operations regulatory and quality.   Eric Easom, AN2 co-founder, chairman, president and CEO, said, “In the near-term, we plan to accelerate our R&D efforts on our boron chemistry platform where we believe we have several promising programs in infectious diseases and oncology.”   As part of an effort to extend the company’s ope...